- MindBio (CSE:MBIO) launched Intox Collect, expanding and accelerating voice‑based data collection for detecting drug and alcohol impairment
- Its AI models analyze 50+ million data points, enabling non‑invasive intoxication prediction using voice alone across multiple substances
- Edge AI kiosk hardware is nearing prototype completion, with on‑site testing planned for late Q2 2026
- MindBio stock (CSE:MBIO) opened trading at C$1.15
Clinical-stage biotechnology company, MindBio Therapeutics (CSE:MBIO) has completed development of Intox Collect, a new software platform designed to expand and accelerate the company’s collection and analysis of intoxication‑related data.
The system enables MindBio to gather and process large volumes of voice and facial recognition data associated with the consumption of a range of substances that affect the human central nervous system.
According to the company, Intox Collect enhances its ability to collect standardized data across multiple substances, including both stimulants and depressants, while improving the efficiency of testing and analytical workflows. The software is intended to support the continued refinement of MindBio’s AI models, which are designed to identify patterns in human voice that correlate with impaired cognition and performance.
MindBio stated that the completion of Intox Collect has enabled the company to rapidly scale data collection and expand predictive modeling beyond alcohol to include additional substances. The platform supports structured testing protocols and large‑scale data analysis, allowing the company to train and validate AI prediction models more quickly than with prior systems.
The company reports that its existing voice intoxication detection model is trained on more than 50 million data points, a figure expected to increase significantly in the coming months as Intox Collect is deployed more broadly. MindBio says its models can predict intoxication using only voice inputs, without requiring biological samples such as breath, blood, urine, or saliva.
The company describes this approach as a potential alternative to conventional testing methods, particularly in environments where frequent or high‑volume testing is required. Industries such as mining, aviation, and construction often operate under regulatory mandates for drug and alcohol testing, where traditional methods can be time‑consuming, costly, and physically invasive.
MindBio indicated that its technology is designed for applications in these regulated environments, where impairment screening is typically episodic and dependent on laboratory‑based analysis. The company’s stated objective is to enable rapid, non‑invasive screening at scale, using computational analysis rather than chemical testing.
The company expects the kiosk hardware to be ready for testing toward the end of Q2 2026. The system is intended to support real‑time screening and to operate in industrial environments where traditional testing infrastructure may be difficult to deploy.
MindBio continues to develop its voice analytics platform alongside data collection capabilities, focusing on expanding its dataset and refining substance‑specific prediction models. The company has not disclosed a timeline for commercial deployment beyond initial testing of its hardware platform but indicated that further updates will follow as development milestones are reached.
Justin Hanka, MindBio’s chief executive officer, summed up the milestone in Monday’s news release, noting that “The digital health diagnostics market represents a significant opportunity for MindBio to leverage its diagnostics technology with a first mover advantage in speech analytics for drug and alcohol intoxication detection. Our technology gives us a significant advantage in using voice to develop non-invasive health diagnostic tools.”
About MindBio Therapeutics
MindBio Therapeutics Corp. is a Vancouver-based biotechnology company creating health prediction technologies using AI and machine learning.
MindBio stock (CSE:MBIO) opened trading around 4 per cent higher at C$1.15 and has risen roughly 50 per cent in the past month.
Join the discussion: Find out what investors are saying about this biotech stock on the MindBio Therapeutics Corp. Bullboard and make sure to explore the rest of Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.